Alex Wiltschko

That's the way in which we're building the business to continue funding the curiosity to market.

move to the next step of Shazam for smell, and then to move to the next step of sniffing cancer.

I love that.

We sell perfumes to get to Shazam for smell, and then we build both of those businesses to ultimately detect disease, which is, that's the Holy Grail.

I mean, I can see a path to detecting scent already today.

We do that for some customers.

So there's an article about this online, but we've sniffed fake Air Jordans at StockX.

So fake shoes smell different than real shoes.

And that has to do with how they're constructed.

So we already have a team and we already have a technology that can smell as well as our nose can.

That's not our main business today.

So we want to continue to develop the technology to take it from the size that it is, which is, I mean, it's not small, but it's not big.

You can hold it and move it around.

We want to make that something that is moving towards being pocketable and more affordable.

It's not quite yet affordable.

But it already solves the real world problems today, but we're going to continue to develop it.

Getting it to something the size of your cell phone may require scientific breakthroughs that we can't even describe today.

So I want to be real, like, that's why we're taking the strategy that we are.

Like, I've looked at all the Enos companies.

I've looked at all the olfaction companies that I've been able to find at least.